Business Description
VYNE Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US5868581027
Description
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 538.63 | |||||
| Equity-to-Asset | 0.86 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -10.06 | |||||
| Beneish M-Score | -3.54 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -84.8 | |||||
| 3-Year EBITDA Growth Rate | 72.7 | |||||
| 3-Year EPS without NRI Growth Rate | 65.2 | |||||
| 3-Year FCF Growth Rate | 68.1 | |||||
| 3-Year Book Growth Rate | -26.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 28.97 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 48.02 | |||||
| 9-Day RSI | 50.21 | |||||
| 14-Day RSI | 50.57 | |||||
| 6-1 Month Momentum % | -42.26 | |||||
| 12-1 Month Momentum % | -51.36 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.13 | |||||
| Quick Ratio | 7.13 | |||||
| Cash Ratio | 6.64 | |||||
| Days Sales Outstanding | 147.45 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -80.4 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -6346.09 | |||||
| Net Margin % | -5849.18 | |||||
| FCF Margin % | -5504.53 | |||||
| ROE % | -51.54 | |||||
| ROA % | -44.38 | |||||
| ROIC % | -943.64 | |||||
| 3-Year ROIIC % | -544.78 | |||||
| ROC (Joel Greenblatt) % | -17198.14 | |||||
| ROCE % | -54.84 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 39.95 | |||||
| PB Ratio | 0.37 | |||||
| Price-to-Tangible-Book | 0.37 | |||||
| EV-to-EBIT | 1.62 | |||||
| EV-to-Forward-EBIT | -0.1 | |||||
| EV-to-EBITDA | 1.62 | |||||
| EV-to-Forward-EBITDA | -0.1 | |||||
| EV-to-Revenue | -103.05 | |||||
| EV-to-Forward-Revenue | 0.19 | |||||
| EV-to-FCF | 1.87 | |||||
| Price-to-Net-Current-Asset-Value | 0.38 | |||||
| Price-to-Net-Cash | 0.41 | |||||
| Earnings Yield (Greenblatt) % | 61.73 | |||||
| FCF Yield % | -95.96 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VYNE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
VYNE Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.486 | ||
| EPS (TTM) ($) | -2.819 | ||
| Beta | 2.51 | ||
| Volatility % | 75.86 | ||
| 14-Day RSI | 50.57 | ||
| 14-Day ATR ($) | 0.122843 | ||
| 20-Day SMA ($) | 1.87635 | ||
| 12-1 Month Momentum % | -51.36 | ||
| 52-Week Range ($) | 1.57 - 4.4808 | ||
| Shares Outstanding (Mil) | 14.75 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
VYNE Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
VYNE Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
VYNE Therapeutics Inc Frequently Asked Questions
What is VYNE Therapeutics Inc(VYNE)'s stock price today?
The current price of VYNE is $1.89. The 52 week high of VYNE is $4.48 and 52 week low is $1.57.
When is next earnings date of VYNE Therapeutics Inc(VYNE)?
The next earnings date of VYNE Therapeutics Inc(VYNE) is 2024-11-13 Est..
Does VYNE Therapeutics Inc(VYNE) pay dividends? If so, how much?
VYNE Therapeutics Inc(VYNE) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers